BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma

12Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

BMI-1 is overexpressed in a variety of cancers, which can activate the immune system to produce antibodies in tumor tissues. In this study, we isolated phage expressing BMI-1 protein by screening of a mixture of nasopharyngeal carcinoma (NPC) cDNA T7 phage library and found that the antibody against BMI-1 was elevated in the sera from NPC patients. BMI-1 mRNA was overexpressed at different levels in seven NPC cell lines compared with normal nasopharyngeal epithelial cell line NP69. Histochemistry showed that patient sera were more reactive with BMI-1 than normal sera. Antibody affinity assay using sera from 40 NPC patients and 54 controls showed that BMI-1 antibody was significantly greater in patient sera than in normal controls (patient 0.791 ± 0.025 and normal 0.488 ± 0.042; p < 0.001) and the BMI-1 autoantibody be significantly related with the progress of NPC (Benign versus LNPC P = 0.001; LNPC versus MNPC p = 0.047). Analysis of the results with logistic regression and receiver operating characteristics (ROC) curves showed that BMI-1 antibody was a modest marker for NPC (sensitivity 0.74 and specificity 0.73; AUC = 0.8044). The showed that BMI-1 antibody as a potential marker of NPC may be rational, and could have diagnostic and prognostic value. ©2008 Landes Bioscience.

Cite

CITATION STYLE

APA

Tong, Y. Q., Liu, B., Huang, J., Liu, Y., Guo, F. J., Zhou, G. H., … Li, G. C. (2008). BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma. Cancer Biology and Therapy, 7(3), 340–344. https://doi.org/10.4161/cbt.7.3.5422

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free